Table 2.
Baseline characteristics of CD22 and bispecific CD19/22 CAR T cells
| Characteristic | CD22 CAR T cells (n = 40) |
CD19/22 CAR T cells (n = 15) |
||||
|---|---|---|---|---|---|---|
| Cryopreserved | Fresh | p value | Cryopreserved | Fresh | p value | |
| n | 21 | 19 | 11 | 8 | ||
| CAR T cells manufactured using cryopreserved MNCs | 15/21 (71%) | 16/19 (84%) | 0.46 | 7/11 (64%) | 3/8 (38%) | 0.37 |
| Median CAR T cell viability at harvest | 97% | 97.5% | 0.59 | 95% | 97.7% | 0.05 |
| Median CAR T cell transfection efficiency (percent Protein L) | 44% | 34% | 0.08 | 70% | 63% | 0.35 |
| Median CAR T cell in vitro fold expansion | 3.02 | 3.405 | 0.99 | 15.01 | 14.07 | 0.49 |
| CAR T cell median CD4:8 ratio | 1.670 | 2.056 | 0.98 | 1.67 | 2.18 | 0.78 |
| Median days of cryopreservation (range) | 24 (6–108) | n/a | n/a | 20 (3–44) | n/a | n/a |
| Median CAR T cell viability at Infusion | 91% | 97.5% | 0.0001 | 86% | 97.7% | <0.0001 |
MNC = mononuclear cell.
Statistically significant p-values are shown in bold.